Skip to main content
Clinical Trials/NCT00259571
NCT00259571
Withdrawn
Phase 2

Prospektive, Randomisierte, Doppelblinde, Mesalazin-kontrollierte ("Double-dummy Verfahren) Multizenter-Studie Zur Beurteilung Der Annahme Der äquivalenten Wirkung Von Intestinal Retardiert Freigesetztem Phosphatidylcholin gegenüber Mesalazin (Non-inferiority Study) in Der Remissionserhaltung Der Colitis Ulcerosa.

Heidelberg University1 site in 1 countryNovember 29, 2005

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Ulcerative Colitis
Sponsor
Heidelberg University
Locations
1
Primary Endpoint
rate of relapses
Status
Withdrawn
Last Updated
12 years ago

Overview

Brief Summary

The purpose of this study is to evaluate if retarded phosphatidylcholine is as effective as mesalazin in preventing an acute episode in ulcerative colitis.

The hypothesis is, that ulcerative colitis is cuased by a defect in the barrier function of the colonic mucus. The background of the study is the finding that the phosphatidylcholine content of the colonic mucus is reduced in patients with ulcerative colitis, in both healthy and inflamed parts of the colon.

Registry
clinicaltrials.gov
Start Date
November 29, 2005
End Date
March 2010
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • diagnosis of ulcerative colitis in remission (CAI 3 or less)
  • signed letter of content
  • no steroids or immunosupressants in the last 6 weeks
  • at least 5 relapses in the last 3 years
  • last relapse was 8 months ago or less
  • complete colonoscopy at entry

Exclusion Criteria

  • pregnancy or breast feeding
  • steroids or immunosuppressants
  • acute episode of UC
  • condition after complete or partial colektomy
  • known intolerance to mesalazin
  • severe medical disease other than colitis

Outcomes

Primary Outcomes

rate of relapses

relapse is defined as an increase of the clinical Rachmilewitz index to 5 or more, but at least 3 points over a period of 14 days

Secondary Outcomes

  • time to the first relapse
  • endoscopic index
  • life quality
  • side effects
  • amount of relapses per year
  • histolgical score

Study Sites (1)

Loading locations...

Similar Trials